Christopher DeSouza
Concepts (408)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cell-Derived Microparticles | 18 | 2025 | 73 | 10.850 |
Why?
| | Endothelium, Vascular | 48 | 2025 | 951 | 9.860 |
Why?
| | Vasodilation | 31 | 2025 | 513 | 6.480 |
Why?
| | Endothelial Cells | 20 | 2025 | 832 | 6.330 |
Why?
| | Endothelin-1 | 18 | 2025 | 177 | 5.610 |
Why?
| | Fibrinolysis | 17 | 2025 | 162 | 4.010 |
Why?
| | Vasoconstriction | 14 | 2025 | 215 | 3.870 |
Why?
| | Tissue Plasminogen Activator | 19 | 2025 | 239 | 3.640 |
Why?
| | Human Umbilical Vein Endothelial Cells | 8 | 2025 | 108 | 2.950 |
Why?
| | Nitric Oxide | 15 | 2025 | 896 | 2.900 |
Why?
| | Vasodilator Agents | 23 | 2025 | 330 | 2.820 |
Why?
| | Obesity | 21 | 2025 | 3027 | 2.780 |
Why?
| | Forearm | 19 | 2025 | 139 | 2.740 |
Why?
| | Hypertension | 14 | 2023 | 1257 | 2.640 |
Why?
| | Spinal Cord Injuries | 5 | 2025 | 236 | 2.520 |
Why?
| | Sleep Deprivation | 6 | 2021 | 204 | 2.480 |
Why?
| | Aging | 40 | 2025 | 1931 | 2.440 |
Why?
| | MicroRNAs | 8 | 2026 | 696 | 2.240 |
Why?
| | Nitric Oxide Synthase Type III | 9 | 2025 | 199 | 2.220 |
Why?
| | Overweight | 9 | 2018 | 594 | 2.030 |
Why?
| | Acetylcholine | 18 | 2025 | 204 | 1.950 |
Why?
| | Exercise | 34 | 2024 | 2133 | 1.720 |
Why?
| | Middle Aged | 115 | 2026 | 35049 | 1.700 |
Why?
| | Prehypertension | 5 | 2015 | 27 | 1.650 |
Why?
| | Apoptosis | 16 | 2025 | 2500 | 1.640 |
Why?
| | Regional Blood Flow | 24 | 2025 | 502 | 1.630 |
Why?
| | Vasomotor System | 2 | 2025 | 47 | 1.550 |
Why?
| | Blood Pressure | 20 | 2021 | 1745 | 1.510 |
Why?
| | Cardiovascular Diseases | 11 | 2021 | 2103 | 1.500 |
Why?
| | HIV Envelope Protein gp120 | 3 | 2019 | 61 | 1.470 |
Why?
| | Polycythemia | 2 | 2021 | 24 | 1.370 |
Why?
| | Stem Cells | 8 | 2012 | 612 | 1.340 |
Why?
| | Sleep | 5 | 2021 | 889 | 1.300 |
Why?
| | Postmenopause | 18 | 2023 | 371 | 1.210 |
Why?
| | NG-Nitroarginine Methyl Ester | 3 | 2024 | 49 | 1.190 |
Why?
| | Male | 96 | 2026 | 70910 | 1.190 |
Why?
| | Nitroprusside | 16 | 2021 | 72 | 1.190 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 25 | 1.150 |
Why?
| | Enzyme Inhibitors | 6 | 2024 | 837 | 1.150 |
Why?
| | Circulating MicroRNA | 2 | 2019 | 25 | 1.130 |
Why?
| | C-Reactive Protein | 7 | 2015 | 417 | 1.120 |
Why?
| | Metabolic Syndrome | 4 | 2016 | 353 | 1.100 |
Why?
| | Humans | 142 | 2026 | 142526 | 1.070 |
Why?
| | Atherosclerosis | 2 | 2023 | 402 | 1.040 |
Why?
| | Nebivolol | 2 | 2017 | 10 | 1.040 |
Why?
| | Cell Movement | 8 | 2014 | 969 | 1.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 50 | 0.990 |
Why?
| | Extracellular Vesicles | 2 | 2026 | 160 | 0.980 |
Why?
| | Peptides, Cyclic | 7 | 2013 | 273 | 0.970 |
Why?
| | Caspase 3 | 5 | 2017 | 249 | 0.970 |
Why?
| | Adult | 71 | 2026 | 39715 | 0.930 |
Why?
| | Inflammation Mediators | 5 | 2024 | 510 | 0.930 |
Why?
| | Erythritol | 1 | 2025 | 2 | 0.930 |
Why?
| | Aged | 68 | 2026 | 25117 | 0.910 |
Why?
| | Female | 86 | 2026 | 76624 | 0.890 |
Why?
| | Sweetening Agents | 1 | 2025 | 55 | 0.880 |
Why?
| | Microvessels | 2 | 2025 | 89 | 0.880 |
Why?
| | Vasoconstrictor Agents | 6 | 2023 | 137 | 0.870 |
Why?
| | Cells, Cultured | 10 | 2025 | 4167 | 0.860 |
Why?
| | Work-Life Balance | 1 | 2024 | 22 | 0.850 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2023 | 92 | 0.820 |
Why?
| | Case-Control Studies | 13 | 2026 | 3604 | 0.780 |
Why?
| | Physical Endurance | 16 | 2024 | 278 | 0.780 |
Why?
| | Goals | 1 | 2024 | 179 | 0.770 |
Why?
| | Dietary Fats | 2 | 2015 | 303 | 0.760 |
Why?
| | Bradykinin | 9 | 2025 | 48 | 0.750 |
Why?
| | Oxidative Stress | 8 | 2025 | 1351 | 0.750 |
Why?
| | Blood Coagulation | 2 | 2021 | 269 | 0.720 |
Why?
| | Biomarkers | 14 | 2026 | 4207 | 0.690 |
Why?
| | Estrogen Replacement Therapy | 9 | 2003 | 142 | 0.690 |
Why?
| | Vascular Diseases | 1 | 2023 | 246 | 0.670 |
Why?
| | Altitude | 3 | 2021 | 478 | 0.650 |
Why?
| | Physical Fitness | 12 | 2005 | 207 | 0.620 |
Why?
| | Acclimatization | 1 | 2021 | 172 | 0.600 |
Why?
| | Hemodynamics | 8 | 2021 | 1114 | 0.600 |
Why?
| | Cross-Sectional Studies | 23 | 2023 | 5700 | 0.580 |
Why?
| | Ascorbic Acid | 3 | 2021 | 180 | 0.570 |
Why?
| | T-Lymphocyte Subsets | 2 | 2011 | 420 | 0.570 |
Why?
| | Endothelium | 3 | 2020 | 119 | 0.570 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2017 | 2053 | 0.570 |
Why?
| | Telomere | 3 | 2010 | 280 | 0.560 |
Why?
| | Metoprolol | 1 | 2017 | 26 | 0.540 |
Why?
| | Hematopoietic Stem Cells | 2 | 2011 | 409 | 0.540 |
Why?
| | HIV | 1 | 2019 | 248 | 0.540 |
Why?
| | Plethysmography | 5 | 2017 | 108 | 0.530 |
Why?
| | Blood Glucose | 7 | 2019 | 2304 | 0.520 |
Why?
| | Hyperglycemia | 2 | 2018 | 365 | 0.510 |
Why?
| | Receptor, Endothelin A | 2 | 2014 | 63 | 0.510 |
Why?
| | Stress, Physiological | 2 | 2017 | 451 | 0.500 |
Why?
| | Plasminogen Activator Inhibitor 1 | 7 | 2023 | 89 | 0.500 |
Why?
| | Cytokines | 4 | 2020 | 2093 | 0.490 |
Why?
| | HIV Infections | 4 | 2019 | 3003 | 0.490 |
Why?
| | Body Mass Index | 15 | 2017 | 2406 | 0.470 |
Why?
| | Nitric Oxide Synthase | 4 | 2017 | 241 | 0.470 |
Why?
| | Young Adult | 13 | 2025 | 13878 | 0.470 |
Why?
| | Cellular Senescence | 1 | 2018 | 221 | 0.460 |
Why?
| | Interleukin-6 | 6 | 2025 | 780 | 0.450 |
Why?
| | Blood Pressure Determination | 2 | 2016 | 144 | 0.450 |
Why?
| | Gender Identity | 2 | 2006 | 130 | 0.440 |
Why?
| | Reactive Oxygen Species | 3 | 2025 | 634 | 0.440 |
Why?
| | Diet, High-Fat | 2 | 2018 | 257 | 0.430 |
Why?
| | Endothelial Progenitor Cells | 1 | 2014 | 20 | 0.410 |
Why?
| | Interleukin-8 | 3 | 2025 | 269 | 0.410 |
Why?
| | Blood Platelets | 1 | 2017 | 389 | 0.400 |
Why?
| | Analysis of Variance | 7 | 2016 | 1313 | 0.400 |
Why?
| | Brain | 2 | 2025 | 2875 | 0.400 |
Why?
| | Glucose | 2 | 2017 | 1038 | 0.400 |
Why?
| | Adiposity | 3 | 2016 | 528 | 0.390 |
Why?
| | Infusions, Intra-Arterial | 5 | 2013 | 62 | 0.390 |
Why?
| | Colony-Forming Units Assay | 6 | 2014 | 94 | 0.380 |
Why?
| | Transcription Factor RelA | 2 | 2024 | 86 | 0.380 |
Why?
| | Blood Vessels | 1 | 2014 | 175 | 0.380 |
Why?
| | Arteries | 7 | 2018 | 260 | 0.380 |
Why?
| | Endothelin A Receptor Antagonists | 4 | 2014 | 26 | 0.370 |
Why?
| | Alkalosis, Respiratory | 2 | 2023 | 2 | 0.370 |
Why?
| | Coronary Disease | 3 | 2007 | 373 | 0.370 |
Why?
| | Inflammation | 5 | 2025 | 2867 | 0.360 |
Why?
| | Oxygen Consumption | 12 | 2024 | 714 | 0.360 |
Why?
| | Body Composition | 14 | 2009 | 706 | 0.360 |
Why?
| | Glucose Intolerance | 1 | 2013 | 146 | 0.360 |
Why?
| | Anti-HIV Agents | 1 | 2019 | 860 | 0.350 |
Why?
| | Muscle, Smooth, Vascular | 5 | 2010 | 448 | 0.350 |
Why?
| | T-Lymphocytes | 2 | 2010 | 2016 | 0.350 |
Why?
| | NF-kappa B | 3 | 2025 | 684 | 0.350 |
Why?
| | Age Factors | 9 | 2025 | 3316 | 0.340 |
Why?
| | Abdominal Fat | 1 | 2011 | 47 | 0.340 |
Why?
| | Fatty Acids | 1 | 2014 | 449 | 0.340 |
Why?
| | Time Factors | 10 | 2021 | 7006 | 0.340 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.340 |
Why?
| | Muscle Tonus | 2 | 2010 | 23 | 0.330 |
Why?
| | HIV Protease Inhibitors | 1 | 2011 | 68 | 0.330 |
Why?
| | Risk Factors | 14 | 2018 | 10593 | 0.330 |
Why?
| | Dyslipidemias | 1 | 2012 | 178 | 0.320 |
Why?
| | Chemotaxis | 1 | 2010 | 122 | 0.320 |
Why?
| | HIV-1 | 2 | 2019 | 890 | 0.320 |
Why?
| | Cholesterol, LDL | 1 | 2012 | 362 | 0.310 |
Why?
| | Health | 1 | 2010 | 83 | 0.310 |
Why?
| | Heart Failure | 1 | 2023 | 2120 | 0.310 |
Why?
| | Postprandial Period | 3 | 2019 | 116 | 0.310 |
Why?
| | Disease | 1 | 2010 | 98 | 0.300 |
Why?
| | Feeding Behavior | 1 | 2015 | 686 | 0.290 |
Why?
| | Flow Cytometry | 4 | 2019 | 1185 | 0.290 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 547 | 0.290 |
Why?
| | Sleep Wake Disorders | 1 | 2013 | 312 | 0.290 |
Why?
| | Muscarinic Agonists | 1 | 2008 | 15 | 0.280 |
Why?
| | Phosphorylation | 2 | 2024 | 1758 | 0.280 |
Why?
| | Fasting | 4 | 2019 | 284 | 0.260 |
Why?
| | Reference Values | 7 | 2016 | 807 | 0.260 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 29 | 0.260 |
Why?
| | Endothelin Receptor Antagonists | 4 | 2011 | 62 | 0.260 |
Why?
| | Exercise Therapy | 4 | 2017 | 456 | 0.250 |
Why?
| | Adult Stem Cells | 1 | 2006 | 40 | 0.250 |
Why?
| | Annexin A1 | 1 | 2026 | 2 | 0.250 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2026 | 2561 | 0.240 |
Why?
| | Dinucleotide Repeats | 1 | 2005 | 6 | 0.240 |
Why?
| | Epigenesis, Genetic | 1 | 2010 | 677 | 0.230 |
Why?
| | Double-Blind Method | 5 | 2021 | 2007 | 0.230 |
Why?
| | Hyperthermia, Induced | 2 | 2023 | 122 | 0.220 |
Why?
| | Myocardial Ischemia | 1 | 2006 | 279 | 0.220 |
Why?
| | Walking | 5 | 2018 | 548 | 0.220 |
Why?
| | Premenopause | 5 | 2002 | 120 | 0.220 |
Why?
| | Physiology | 1 | 2024 | 13 | 0.210 |
Why?
| | Adipose Tissue | 6 | 2005 | 649 | 0.210 |
Why?
| | Blood Flow Velocity | 3 | 2012 | 415 | 0.210 |
Why?
| | Estrogen Receptor alpha | 1 | 2005 | 146 | 0.210 |
Why?
| | Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.210 |
Why?
| | Quadriplegia | 1 | 2023 | 13 | 0.210 |
Why?
| | Signal Transduction | 5 | 2025 | 5163 | 0.210 |
Why?
| | Carotid Arteries | 5 | 2003 | 202 | 0.210 |
Why?
| | Antihypertensive Agents | 4 | 2013 | 511 | 0.200 |
Why?
| | Hypertrophy | 2 | 2023 | 134 | 0.200 |
Why?
| | Actinin | 1 | 2023 | 12 | 0.200 |
Why?
| | von Willebrand Factor | 1 | 2023 | 84 | 0.200 |
Why?
| | Thrombophilia | 1 | 2023 | 90 | 0.200 |
Why?
| | Troponin T | 1 | 2023 | 63 | 0.190 |
Why?
| | Contraceptives, Oral | 1 | 2002 | 38 | 0.190 |
Why?
| | Running | 5 | 2000 | 229 | 0.190 |
Why?
| | Receptor, Endothelin B | 2 | 2014 | 46 | 0.190 |
Why?
| | Vaping | 1 | 2023 | 65 | 0.180 |
Why?
| | Career Choice | 1 | 2024 | 234 | 0.180 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 107 | 0.180 |
Why?
| | Breathing Exercises | 1 | 2021 | 21 | 0.180 |
Why?
| | Inhalation | 1 | 2021 | 29 | 0.170 |
Why?
| | Respiratory Muscles | 1 | 2021 | 36 | 0.170 |
Why?
| | Diet, Sodium-Restricted | 1 | 2001 | 38 | 0.170 |
Why?
| | South America | 1 | 2021 | 56 | 0.170 |
Why?
| | Estradiol | 1 | 2025 | 524 | 0.170 |
Why?
| | Colorado | 6 | 2024 | 4638 | 0.170 |
Why?
| | Peru | 1 | 2021 | 61 | 0.170 |
Why?
| | Sex Characteristics | 4 | 2017 | 790 | 0.170 |
Why?
| | Diet, Carbohydrate-Restricted | 2 | 2018 | 37 | 0.170 |
Why?
| | Lymphocyte Count | 2 | 2011 | 167 | 0.170 |
Why?
| | Endothelins | 1 | 2021 | 63 | 0.170 |
Why?
| | Healthy Lifestyle | 1 | 2021 | 35 | 0.170 |
Why?
| | Drug Administration Schedule | 2 | 2016 | 772 | 0.170 |
Why?
| | Fibrosis | 1 | 2023 | 545 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2015 | 1225 | 0.160 |
Why?
| | Cytochromes c | 2 | 2010 | 59 | 0.160 |
Why?
| | Transforming Growth Factor beta | 1 | 2023 | 479 | 0.160 |
Why?
| | Chemokine CXCL12 | 2 | 2010 | 85 | 0.160 |
Why?
| | Piperidines | 2 | 2013 | 220 | 0.160 |
Why?
| | Fibrinogen | 2 | 1998 | 179 | 0.160 |
Why?
| | Oligopeptides | 2 | 2013 | 266 | 0.150 |
Why?
| | Physical Exertion | 2 | 1998 | 209 | 0.150 |
Why?
| | Fever | 2 | 2020 | 310 | 0.150 |
Why?
| | Insulin Glargine | 1 | 2019 | 85 | 0.150 |
Why?
| | Chronic Disease | 1 | 2025 | 1815 | 0.150 |
Why?
| | Cell Proliferation | 1 | 2006 | 2514 | 0.150 |
Why?
| | E-Selectin | 1 | 2018 | 58 | 0.150 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 229 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 363 | 0.150 |
Why?
| | HIV Antibodies | 1 | 2019 | 66 | 0.140 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 421 | 0.140 |
Why?
| | Telomerase | 2 | 2011 | 249 | 0.140 |
Why?
| | Phenotype | 2 | 2021 | 3184 | 0.140 |
Why?
| | Brachial Artery | 3 | 2017 | 207 | 0.140 |
Why?
| | Myocytes, Cardiac | 1 | 2023 | 539 | 0.140 |
Why?
| | Heat-Shock Response | 1 | 2018 | 77 | 0.140 |
Why?
| | Adrenergic beta-1 Receptor Antagonists | 1 | 2017 | 8 | 0.140 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 41 | 0.140 |
Why?
| | Antioxidants | 1 | 2021 | 594 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2017 | 5270 | 0.140 |
Why?
| | Dietary Carbohydrates | 1 | 2018 | 152 | 0.140 |
Why?
| | Biomedical Research | 1 | 2024 | 692 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2005 | 1067 | 0.130 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 143 | 0.130 |
Why?
| | Pilot Projects | 1 | 2023 | 1829 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2021 | 11298 | 0.130 |
Why?
| | Heart | 1 | 2021 | 627 | 0.130 |
Why?
| | Lipids | 3 | 2009 | 687 | 0.130 |
Why?
| | Infusions, Intraosseous | 1 | 2016 | 19 | 0.120 |
Why?
| | Prognosis | 3 | 2018 | 4112 | 0.120 |
Why?
| | Anthropometry | 2 | 2011 | 208 | 0.120 |
Why?
| | Enzyme Activation | 1 | 2017 | 785 | 0.120 |
Why?
| | Triglycerides | 3 | 2005 | 512 | 0.120 |
Why?
| | Baroreflex | 3 | 2001 | 57 | 0.120 |
Why?
| | Substance P | 2 | 2008 | 37 | 0.120 |
Why?
| | Isoproterenol | 2 | 2008 | 101 | 0.110 |
Why?
| | Insulin | 2 | 2005 | 2492 | 0.110 |
Why?
| | Down-Regulation | 1 | 2017 | 639 | 0.110 |
Why?
| | Blood Circulation | 1 | 2015 | 44 | 0.110 |
Why?
| | Insulin Resistance | 2 | 2003 | 1229 | 0.110 |
Why?
| | Interleukin-18 | 2 | 2006 | 236 | 0.110 |
Why?
| | Hot Temperature | 1 | 2017 | 406 | 0.110 |
Why?
| | Cross-Over Studies | 4 | 2017 | 580 | 0.100 |
Why?
| | Peptides | 1 | 2019 | 974 | 0.100 |
Why?
| | Regression Analysis | 5 | 2011 | 1013 | 0.100 |
Why?
| | Physical Education and Training | 2 | 2024 | 73 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2015 | 310 | 0.100 |
Why?
| | Hydrocortisone | 1 | 2015 | 310 | 0.100 |
Why?
| | Cholinergic Agonists | 1 | 2011 | 7 | 0.090 |
Why?
| | Injections, Intravenous | 1 | 2012 | 203 | 0.090 |
Why?
| | Blood Volume | 4 | 1999 | 65 | 0.090 |
Why?
| | Obesity, Abdominal | 1 | 2011 | 45 | 0.090 |
Why?
| | Waist Circumference | 1 | 2011 | 136 | 0.080 |
Why?
| | Plaque, Atherosclerotic | 1 | 2011 | 58 | 0.080 |
Why?
| | Vital Capacity | 2 | 2002 | 308 | 0.080 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2011 | 188 | 0.080 |
Why?
| | Femoral Artery | 2 | 2002 | 188 | 0.080 |
Why?
| | Circadian Rhythm | 1 | 2015 | 510 | 0.080 |
Why?
| | Plant Lectins | 1 | 2010 | 8 | 0.080 |
Why?
| | Staurosporine | 1 | 2010 | 20 | 0.080 |
Why?
| | Prevalence | 3 | 2014 | 2817 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1391 | 0.080 |
Why?
| | Cholesterol | 2 | 2005 | 404 | 0.080 |
Why?
| | Estrogens | 2 | 2003 | 371 | 0.080 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2010 | 89 | 0.080 |
Why?
| | Bone Diseases, Metabolic | 1 | 2010 | 64 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 206 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 310 | 0.080 |
Why?
| | Cerebrovascular Circulation | 2 | 2023 | 271 | 0.080 |
Why?
| | CD3 Complex | 1 | 2009 | 107 | 0.080 |
Why?
| | Leg | 2 | 2001 | 239 | 0.070 |
Why?
| | Aged, 80 and over | 6 | 2003 | 8020 | 0.070 |
Why?
| | Life Style | 5 | 2003 | 482 | 0.070 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2011 | 371 | 0.070 |
Why?
| | Norepinephrine | 1 | 2009 | 191 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 440 | 0.070 |
Why?
| | Up-Regulation | 1 | 2012 | 857 | 0.070 |
Why?
| | Endothelin-Converting Enzymes | 1 | 2008 | 9 | 0.070 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2008 | 31 | 0.070 |
Why?
| | Metalloendopeptidases | 1 | 2008 | 59 | 0.070 |
Why?
| | Adolescent | 6 | 2025 | 22326 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 320 | 0.070 |
Why?
| | Methacholine Chloride | 1 | 2008 | 50 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2008 | 174 | 0.070 |
Why?
| | Hemiplegia | 2 | 1997 | 21 | 0.070 |
Why?
| | Arm | 1 | 2007 | 109 | 0.060 |
Why?
| | Coronary Circulation | 1 | 2007 | 134 | 0.060 |
Why?
| | Risk Assessment | 1 | 2016 | 3562 | 0.060 |
Why?
| | Probability | 1 | 2007 | 307 | 0.060 |
Why?
| | Lipoproteins, LDL | 1 | 2006 | 112 | 0.060 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2005 | 17 | 0.060 |
Why?
| | Thymidine | 1 | 2005 | 60 | 0.060 |
Why?
| | Muscle, Skeletal | 3 | 2002 | 1772 | 0.060 |
Why?
| | DNA Methylation | 1 | 2010 | 657 | 0.060 |
Why?
| | Anaerobic Threshold | 2 | 2005 | 28 | 0.050 |
Why?
| | Weight Loss | 1 | 2010 | 803 | 0.050 |
Why?
| | Bone Marrow Cells | 1 | 2005 | 317 | 0.050 |
Why?
| | France | 1 | 2024 | 38 | 0.050 |
Why?
| | Hypocapnia | 1 | 2023 | 8 | 0.050 |
Why?
| | Hyperventilation | 1 | 2023 | 14 | 0.050 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 449 | 0.050 |
Why?
| | Thrombosis | 1 | 2007 | 399 | 0.050 |
Why?
| | History, 21st Century | 1 | 2024 | 220 | 0.050 |
Why?
| | Compliance | 4 | 2008 | 50 | 0.050 |
Why?
| | Body Weight | 2 | 2005 | 997 | 0.050 |
Why?
| | Fenofibrate | 1 | 2003 | 27 | 0.050 |
Why?
| | Muscarinic Antagonists | 1 | 2003 | 30 | 0.050 |
Why?
| | History, 20th Century | 1 | 2024 | 327 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2006 | 1084 | 0.050 |
Why?
| | Hypertriglyceridemia | 1 | 2003 | 39 | 0.050 |
Why?
| | Adenine | 1 | 2005 | 337 | 0.050 |
Why?
| | Bicycling | 1 | 2024 | 120 | 0.050 |
Why?
| | Heart Rate | 4 | 2001 | 840 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 622 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2007 | 1977 | 0.050 |
Why?
| | Exercise Test | 3 | 2005 | 623 | 0.050 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 97 | 0.050 |
Why?
| | Carotid Artery Diseases | 1 | 2002 | 63 | 0.050 |
Why?
| | Carbon Dioxide | 1 | 2023 | 241 | 0.040 |
Why?
| | Tunica Intima | 4 | 2002 | 76 | 0.040 |
Why?
| | Progesterone | 1 | 2003 | 258 | 0.040 |
Why?
| | Universities | 1 | 2024 | 451 | 0.040 |
Why?
| | Systole | 1 | 2001 | 175 | 0.040 |
Why?
| | Heart Conduction System | 1 | 2001 | 92 | 0.040 |
Why?
| | Cardiovascular Physiological Phenomena | 1 | 2000 | 44 | 0.040 |
Why?
| | Ultrasonography | 5 | 2002 | 767 | 0.040 |
Why?
| | Mexican Americans | 1 | 2001 | 114 | 0.040 |
Why?
| | Knee | 1 | 2000 | 69 | 0.040 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2019 | 17 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 2081 | 0.040 |
Why?
| | Hemorheology | 1 | 2018 | 22 | 0.040 |
Why?
| | Social Class | 1 | 2001 | 271 | 0.040 |
Why?
| | Body Constitution | 1 | 1998 | 54 | 0.040 |
Why?
| | Energy Intake | 2 | 1998 | 513 | 0.040 |
Why?
| | Drug Combinations | 1 | 2019 | 369 | 0.040 |
Why?
| | Diet, Fat-Restricted | 1 | 2018 | 77 | 0.040 |
Why?
| | Oxygen | 1 | 2024 | 991 | 0.040 |
Why?
| | Hemostasis | 1 | 1998 | 100 | 0.030 |
Why?
| | Plasminogen Activators | 1 | 1997 | 7 | 0.030 |
Why?
| | Cervical Vertebrae | 1 | 2018 | 149 | 0.030 |
Why?
| | Vascular Resistance | 1 | 1998 | 364 | 0.030 |
Why?
| | Gait | 2 | 1997 | 321 | 0.030 |
Why?
| | United States | 1 | 2014 | 15447 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 5858 | 0.030 |
Why?
| | Movement Disorders | 1 | 1997 | 67 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 1997 | 100 | 0.030 |
Why?
| | Chromium | 1 | 1996 | 17 | 0.030 |
Why?
| | Weight Lifting | 1 | 1996 | 32 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 580 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2025 | 2608 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2761 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1247 | 0.030 |
Why?
| | Hypoxia | 1 | 2021 | 1166 | 0.030 |
Why?
| | Antigens | 1 | 1996 | 349 | 0.030 |
Why?
| | Swimming | 3 | 1999 | 49 | 0.030 |
Why?
| | Menopause | 1 | 1997 | 317 | 0.030 |
Why?
| | Melatonin | 1 | 2015 | 163 | 0.030 |
Why?
| | Defibrillators, Implantable | 1 | 1997 | 318 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1642 | 0.020 |
Why?
| | Brain Ischemia | 1 | 1997 | 351 | 0.020 |
Why?
| | Tunica Media | 2 | 2001 | 36 | 0.020 |
Why?
| | Sex Factors | 1 | 1996 | 2074 | 0.020 |
Why?
| | Animals | 3 | 2024 | 37697 | 0.020 |
Why?
| | Cardiac Output | 2 | 1998 | 178 | 0.020 |
Why?
| | Bone Density | 1 | 2010 | 499 | 0.020 |
Why?
| | Prospective Studies | 4 | 2001 | 7862 | 0.020 |
Why?
| | Stroke Volume | 2 | 1998 | 606 | 0.010 |
Why?
| | Hemostatics | 1 | 2005 | 60 | 0.010 |
Why?
| | Hypolipidemic Agents | 1 | 2003 | 93 | 0.010 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2003 | 158 | 0.010 |
Why?
| | Lipoproteins | 1 | 2003 | 163 | 0.010 |
Why?
| | Blood Viscosity | 1 | 2001 | 18 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2002 | 268 | 0.010 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.010 |
Why?
| | Habits | 1 | 2001 | 51 | 0.010 |
Why?
| | Thigh | 1 | 2000 | 49 | 0.010 |
Why?
| | Thinness | 1 | 2000 | 97 | 0.010 |
Why?
| | Mexico | 1 | 2001 | 230 | 0.010 |
Why?
| | Elasticity | 1 | 2000 | 193 | 0.010 |
Why?
| | Erythrocyte Volume | 1 | 1999 | 6 | 0.010 |
Why?
| | Plasma Volume | 1 | 1999 | 20 | 0.010 |
Why?
| | Femur | 1 | 2001 | 264 | 0.010 |
Why?
| | Stress, Mechanical | 1 | 2001 | 488 | 0.010 |
Why?
| | Supine Position | 1 | 1998 | 38 | 0.010 |
Why?
| | Posture | 1 | 1999 | 193 | 0.010 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 152 | 0.010 |
Why?
| | Hematocrit | 1 | 1997 | 104 | 0.010 |
Why?
| | Rest | 1 | 1997 | 128 | 0.010 |
Why?
| | Electric Conductivity | 1 | 1997 | 85 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1319 | 0.010 |
Why?
| | Ventricular Fibrillation | 1 | 1997 | 62 | 0.010 |
Why?
| | Electrodes, Implanted | 1 | 1997 | 113 | 0.010 |
Why?
| | Hyperlipidemias | 1 | 1997 | 126 | 0.010 |
Why?
| | Diabetes Complications | 1 | 1997 | 222 | 0.010 |
Why?
| | Equipment Design | 1 | 1997 | 530 | 0.010 |
Why?
| | Tachycardia, Ventricular | 1 | 1997 | 178 | 0.010 |
Why?
| | Electrocardiography | 1 | 1998 | 628 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 1998 | 1508 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1626 | 0.010 |
Why?
| | Stroke | 1 | 2002 | 1209 | 0.010 |
Why?
| | Heart Arrest | 1 | 1997 | 398 | 0.010 |
Why?
| | Survival Rate | 1 | 1997 | 1995 | 0.010 |
Why?
| | Length of Stay | 1 | 1997 | 1273 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1997 | 935 | 0.010 |
Why?
| | Smoking | 1 | 1997 | 1579 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2003 | 16626 | 0.000 |
Why?
|
|
DeSouza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|